U.S., Dec. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07294300) titled 'A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological Malignancies' on Dec. 08.
Brief Summary: This study is an open-label, dose-escalation and efficacy-expansion Phase I clinical trial to evaluate the safety, tolerability, PK profile, immunogenicity, and preliminary antitumor activity of QLS2313 as a monotherapy in patients with relapsed/refractory hematological malignancies.
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Relapsed/Refractory Hematological Malignancies
Intervention:
DRUG: QLS2313
CD79b/CD3/CD20;first in human; subcutaneous injection
Recruitment Status: NOT_YET_RECRUITI...